Visceral leishmaniasis (VL) is a vector-borne parasitic disease targeting tissue macrophages.
It is among the most neglected infectious diseases. Classical manifestations of VL include …

Background Treatment of Plasmodium vivax malaria requires the clearing of asexual parasites,
but relapse can be prevented only if dormant hypnozoites are cleared from the liver (a …

Leishmania aethiopica is the etiological agent of cutaneous leishmaniasis (CL) in Ethiopia
and can cause severe and complicated cases such as diffuse CL (DCL), mucocutaneous …

Visceral leishmaniasis (VL) is a disseminated protozoan infection caused by Leishmania
donovani and Leishmania infantum. 1 Exceptionally, dermatotropic species can visceralize and …

Visceral Leishmaniasis (VL) is an important protozoan opportunistic disease in HIV patients
in endemic areas. East Africa is second to the Indian subcontinent in the global VL caseload …

Background The existing seroepidemiological data on viral hepatitis in Ethiopia showed a
wide variation in prevalence pattern and the clinical and public health burden have been …

Background The 2014/2015 Ebola outbreak was the most sustained in history. In Guinea,
we compared trends in family planning, antenatal care, and institutional deliveries over the …

Background In Africa, fewer than half of patients receiving therapy for multidrug-resistant TB
(MDR TB) are successfully treated, with poor outcomes reported for HIV-coinfected patients. …

A novel pan- Leishmania loop-mediated isothermal amplification (LAMP) assay for the
diagnosis of cutaneous and visceral leishmaniasis (CL and VL) that can be used in near-patient …

Background: Despite the great impact of information and communication technologies on
clinical practice and on the quality of health services, this trend has been almost exclusive to …